Bortezomib improved the joint manifestations of rheumatoid arthritis in three patients

Slim Lassoued; Chantal Moyano; Mounir Beldjerd; Pierre Pauly; Donia Lassoued; Thierry Billey

doi:10.1016/j.jbspin.2019.01.019

Bortezomib improved the joint manifestations of rheumatoid arthritis in three patients

Joint Bone Spine. 2019 May;86(3):381-382. doi: 10.1016/j.jbspin.2019.01.019. Epub 2019 Feb 6.

Authors

Slim Lassoued¹, Chantal Moyano², Mounir Beldjerd², Pierre Pauly³, Donia Lassoued², Thierry Billey²

Affiliations

¹ Service de rhumatologie, centre hospitalier Jean-Rougié Cahors 46000, France. Electronic address: [email protected].
² Service de rhumatologie, centre hospitalier Jean-Rougié Cahors 46000, France.
³ Service de rhumatologie, centre hospitalier Jean-Rougié Cahors 46000, France; Service de rhumatologie, centre hospitalier 47000 Villeneuve-sur-Lot, France.

PMID: 30735806
DOI: 10.1016/j.jbspin.2019.01.019

Abstract

The proteasome inhibitor bortezomib has been proven effective in the treatment of multiple myeloma. We report on 3 patients with rheumatoid arthritis and multiple myeloma in whom bortezomib therapy was associated with improvements in the joint manifestations. The contribution to this effect of the concomitant glucocorticoid therapy is discussed.

Keywords: Multiple myeloma; Proteasome inhibitor; Rheumatoid arthritis.

MeSH terms

Aged
Arthritis, Rheumatoid / diagnosis
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / epidemiology*
Bortezomib / administration & dosage*
Comorbidity
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / epidemiology*
Pain Measurement
Prognosis
Proteasome Inhibitors / administration & dosage
Range of Motion, Articular / drug effects
Sampling Studies
Treatment Outcome

Substances

Proteasome Inhibitors
Bortezomib